News Search Results
Aug 12, 2026, 09:02 ET Philadelphia Sleep Physician Dr. Funke Afolabi-Brown Featured on FOX 29, Launches Free "Perimenopause Sleep Guide" for Women Struggling to Sleep in Midlife
standard sleep advice so often falls short for women in midlife, and what the evidence actually supports — including cognitive behavioral therapy for insomnia (CBT-I), addressing hot flashes and night sweats directly, ruling out sleep-disordered breathing, and aligning sleep timing with a woman's individual
More news about: The Restful Sleep Place
Aug 11, 2026, 07:50 ET SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).
(melatonin extended-release tablets) is now available across Canada. SLENYTO® is approved as a prescription medicine in Canada for the treatment of insomnia in children and adolescents aged 2 to <18 years with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene
More news about: Kye Pharmaceuticals Inc.
Aug 10, 2026, 14:59 ET Insomnia Cookies Gives the Class of 2030 30,000 Free Freshman 6-Packs of Cookies
begins its next chapter, Insomnia Cookies wishes students the best — and looks forward to being there all year long for late-night study breaks, much-needed pick-me-ups, new-friend hangouts and every celebration along the way.ABOUT INSOMNIA COOKIESInsomnia Cookies is a rapidly expanding
More news about: Insomnia Cookies
Aug 10, 2026, 10:31 ET Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
said that among emerging therapies, seltorexant is expected to demonstrate moderate-to-strong uptake potential, particularly in MDD patients with insomnia and sleep-related symptoms, reflecting growing interest in orexin-targeted therapies.Major Depressive Disorder Market Analysis
More news about: DelveInsight Business Research, LLP
Aug 05, 2026, 09:00 ET Headlands Research Expands Pacific Northwest Presence with New Clinical Research Site in Bellingham, Washington
615,000 people within a 50-mile radius. Local physicians logged more than 1,200 diagnosis claims across depression, bipolar disorder, anxiety, and insomnia in 2025, a participant pool well-suited to Dr. Bogoyas's specialization. The site is expected to support neuropsychiatric and adjacent therapeutic
More news about: Headlands Research
Aug 04, 2026, 09:00 ET Delightree Raises $25M to Build the Agentic Operating System for Franchise and Multi-Unit Brands
operating model for how these businesses train teams, maintain standards, and coordinate execution across locations.""Backing 7 Brew Coffee, Insomnia Cookies, and Sweetgreen early showed us what separates local brands from national ones: technology once reserved for the largest chains," said Daniel
More news about: Delightree
Jul 27, 2026, 09:52 ET HoneyNaps Registers as Contract Research Organization (CRO), Accelerating AI-Powered Clinical Trial Analytics
USD 22.8 billion in 2025 to USD 36.9 billion by 2034. Sleep is increasingly recognized not only as a critical endpoint for sleep disorders such as insomnia and obstructive sleep apnea, but also as an important digital biomarker in clinical research involving obesity, cardiovascular disease, neurodegenerative
More news about: HoneyNaps
Jul 27, 2026, 09:10 ET Niagara-On-The-Lake Alt-Folk Rocker Ryan Bissell Releases Debut Single "Get Up Get Ready"
gaping wound from a stingray sting that refused to heal for six months.Months of antibiotics wrecked his stomach and triggered a stretch of insomnia that took a serious toll on his mental health, leaving him wide awake most nights until sunrise. Music became his outlet. He challenged himself to
More news about: Ryan Bissell
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
neurologic toxicity in 6%. Neurologic toxicities reported in ≥5% of patients included headache (27%), sensory neuropathy (16%), motor dysfunction (15%), insomnia (12%), encephalopathy (11%), and dizziness (8%). Fatal neurologic toxicity occurred in 0.4% of patients, including Guillain-Barré syndrome and status
More news about: Johnson & Johnson
Jul 20, 2026, 09:33 ET GROW THERAPY DATA REVEAL NEARLY 40% OF ONLINE THERAPY-GOERS HAVE ATTENDED A VIRTUAL THERAPY SESSION FROM BED
transitions were the fastest-growing reason people sought therapy, increasing 168% year-over-year, followed by coping skills (+152%), trauma and PTSD (+152%), insomnia and sleep (+151%), parenting (+145%), and postpartum concerns (+128%).Optimism was the most common benefit, reported by 38% of people
More news about: Grow Therapy
Jul 18, 2026, 05:00 ET Innovative CBD-Coated Bedding Clinically Proven to Improve Sleep Quality: Song Beam Bedding and China Medical University's Joint Study Published in International Journal Healthcare
scientific backing for our CBD microcapsule technology but also offers a completely new, safe, and effective sleep aid option for millions suffering from insomnia and anxiety worldwide."Song Beam Bedding continues to be committed to sleep technology innovation. Currently, its CBD Herbal Anti-Anxiety series
More news about: Song Beam Bedding Co., Ltd.
Jul 16, 2026, 12:00 ET Apollo Neuroscience Announces Publication of Landmark Clinical Study Demonstrating Apollo Wearable Use Yields an Average of 46 More Minutes of Sleep Per Night
intervention. It points toward a future where we help the nervous system naturally create healthier sleep, giving millions of people with chronic insomnia and short sleep a technology option that provides comparable sleep improvement to industry-leading prescription sleep medications."Apollo's
More news about: Apollo Neuroscience
Jul 16, 2026, 10:05 ET Sleep disorders don't just exhaust you. A new Florida International University study shows they change your brain
by side, looking for both shared and distinct patterns in brain structure. Researchers analyzed two major categories: dyssomnias, including insomnia and sleep apnea, which make it difficult to fall or stay asleep; and parasomnias, including sleepwalking, nightmare disorder and sleep terrors, which
More news about: Florida International University
Jul 15, 2026, 15:28 ET Insomnia Cookies Served 10 Million Scoops Last Year--And Most People Still Don't Know It Makes Its Own Ice Cream
much more to discover at Insomnia beyond the warm cookies people already know and love," said Seth Berkowitz, founder and CEO of Insomnia Cookies. "We make our own ice cream and fill it with those same delicious cookies, creating flavors you can only experience at Insomnia. I want people to come in this
More news about: Insomnia Cookies
Jul 14, 2026, 08:00 ET Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
oxygen desaturation index. AD109 was generally well-tolerated in its Phase 3 clinical program, and the most common adverse events were dry mouth, insomnia and nausea, which were consistent with earlier AD109 clinical trials.About AD109 AD109 is investigational and is designed
More news about: Apnimed, Inc.
Jul 13, 2026, 07:30 ET Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research
disorders. Monitor for signs of perforation and bleedingActhar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravatedPatients with comorbid
More news about: Keenova Therapeutics
Jul 08, 2026, 12:43 ET Doctor's Best Adds New Magnesium and Creatine Powders to Product Line
as part of a nighttime routine to promote relaxation and quality sleep. In a recent clinical trial, magnesium supplementation was shown to decrease insomnia severity scores compared to placebo in adults with poor sleep quality, supporting its role in sleep health.2"Our goal is to make
More news about: Doctor's Best
Jun 29, 2026, 03:58 ET Positive interim analysis advances Avecho Phase III insomnia program
Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis evaluating its TPM®-enhanced cannabidiol (CBD) capsule. The interim analysis represents
More news about: Avecho Biotechnology Limited
Jun 22, 2026, 11:49 ET Ryde: Tackles SLEEP, Launching Its Newest Wellbeing Functional Shot In Partnership With Rob Gronkowski
may cause drowsiness or sleepiness. Do not take when driving or operating heavy machinery or consuming alcohol. Ryde: Sleep is not intended to treat insomnia or other sleep disorders and is not a substitute for healthy sleep practices. Keep out of reach of children.
More news about: Ryde:
Jun 18, 2026, 12:31 ET Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
othersScope of the Insomnia Market ReportInsomnia Patient Population ForecastInsomnia Therapeutics Market SizeInsomnia Pipeline AnalysisInsomnia Market Size and TrendsInsomnia Market OpportunityInsomnia Market Unmet NeedsKOL's
More news about: DelveInsight Business Research, LLP
Jun 17, 2026, 08:46 ET Josh Helms Highlights PPOA's Expanded Focus on Complex Pain Conditions Beyond Musculoskeletal Care
painENT / OtolaryngologyFacial neuralgia, cervicofacial painSleep MedicinePain-driven insomnia, nocturnal pain syndromes"Many patients and healthcare providers are surprised to learn how many non-musculoskeletal conditions
More news about: Physician Partners of America
Jun 16, 2026, 16:05 ET Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
patients at recommended doses, one patient reported insomnia following abrupt discontinuation of XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory
More news about: Jazz Pharmaceuticals plc
Jun 16, 2026, 12:30 ET Insomnia Cookies and WBDGCP Team Up for an Out-Of-This-World Supergirl-Inspired Cookie Drop
www.InsomniaCookies.com.About Insomnia CookiesInsomnia Cookies is a rapidly expanding late-night bakery concept headquartered in Philadelphia, PA. Founded at the University of Pennsylvania by then-student Seth Berkowitz, Insomnia Cookies has been feeding the insatiable hunger
More news about: Insomnia Cookies
Jun 16, 2026, 11:26 ET Kong Announces Insomnia and Kong Konnect Integration to Unify API and AI Development Workflows
directly within Insomnia. This enables developers to seamlessly pull environment configurations from Konnect into Insomnia with a single click.A Single Source of Truth: When platform teams update API specifications in Konnect, those changes automatically reflect in Insomnia. This eliminates
More news about: Kong Inc.
Jun 15, 2026, 10:25 ET SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.